All In Biotech

Drug Trial Radar · NCT05559541

Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors

A Multicenter, Open-Label, Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of AK119 Combined With AK104 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Feb 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

33

Actual

Start

Dec 15, 2022

Primary completion

May 31, 2024

Study completion May 31, 2024

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Sep 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase Ib/II Study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK119 combined with AK104 in tumor patients.

Conditions

  • Solid Tumor, Adult

Interventions

  • AK119Drug

    AK119 is an anti-CD73 monoclonal antibody.

  • AK104Drug

    AK104 is an anti-PD-1 and CTLA-4 bispecific antibody.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with dose limiting toxicities (DLTs)Time frame: During the first 3 or 4 weeks
  2. Number of subjects with adverse events (AEs)Time frame: From the time of informed consent signed through 90 days after the last dose of study drug.
  3. Objective response rate (ORR)Time frame: Up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University Cancer Insitute & Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.